How has been the historical performance of Divi's Lab.?

Revenue and Profit Growth Trends

Over the seven-year period ending March 2025, Divi's Lab. has seen its net sales rise substantially from ₹4,946 crores in 2019 to ₹9,360 crores in 2025. Despite a slight dip in 2023, the overall trend reflects strong top-line expansion, with a compound annual growth rate (CAGR) exceeding 12%. Operating profit before depreciation and interest (PBDIT) has also shown resilience, reaching ₹3,320 crores in 2025, up from ₹2,027 crores in 2019. The operating profit margin, excluding other income, has fluctuated but remained healthy, peaking at over 43% in 2022 before settling at approximately 31.7% in 2025.

Profit after tax (PAT) has mirrored this growth, climbing from ₹1,353 crores in 2019 to ₹2,191 crores in 2025. Earnings per share (EPS) have followed suit, rising from around ₹51 in 2019 to ₹83 in 2025, signalling enhanced shareholder value. The PAT margin has remained robust, consistently above 20%, with a high of 33% in 2022, underscoring efficient cost management and operational leverage.

Balance Sheet Strength and Asset Base

Divi's Lab.'s balance sheet has strengthened significantly, with shareholder's funds rising from ₹7,310 crores in 2020 to nearly ₹14,969 crores in 2025. The company's reserves have more than doubled over this period, reflecting retained earnings and capital accumulation. Book value per share has increased steadily, reaching ₹565 in 2025 from ₹275 in 2020, indicating growing net asset value per share.

The company maintains a near-zero debt profile, with total debt reduced to a nominal ₹2 crores in 2025 from ₹33 crores in 2020, highlighting a conservative capital structure and low financial risk. Total assets have expanded from ₹8,531 crores in 2020 to ₹16,921 crores in 2025, supported by investments in gross block assets and capital work in progress, which have nearly doubled in value over the period.

Cash Flow and Liquidity Position

Cash flow from operating activities has generally trended upwards, reaching ₹1,653 crores in 2025 compared to ₹1,215 crores in 2020. Despite fluctuations in working capital changes, the company has maintained positive net cash inflows in recent years, with a closing cash and bank balance of ₹3,715 crores in 2025. Investing activities have seen significant outflows in some years, reflecting capital expenditure and expansion efforts, while financing activities have consistently been negative, indicating repayments or dividend distributions.

This strong liquidity position supports Divi's Lab.'s operational needs and strategic investments, underpinning its capacity for sustainable growth.

Summary of Historical Performance

In summary, Divi's Lab. has exhibited a commendable historical performance characterised by steady revenue growth, expanding profitability, and a strong balance sheet with minimal debt. The company’s operating and net profit margins have remained healthy, reflecting efficient cost control and operational excellence. Its cash flow generation has supported ongoing investments and financial stability, while shareholder equity has grown substantially, enhancing intrinsic value.

While some year-on-year variations in margins and cash flows are evident, the overall trajectory points to a well-managed enterprise with solid fundamentals. Investors seeking exposure to a pharmaceutical and chemical sector leader may find Divi's Lab.'s historical performance reassuring as a foundation for future growth prospects.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →